Success Metrics

Completion Rate
0%(0/1)
Active Trials
7(88%)
Terminated
1(13%)

Phase Distribution

Ph phase_1
1
13%
Ph phase_2
5
63%
Ph phase_3
2
25%

Phase Distribution

1

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
1(12.5%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

7

trials recruiting

Total Trials

8

all time

Status Distribution
Active(7)
Terminated(1)

Detailed Status

Recruiting6
Terminated1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
7
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (12.5%)
Phase 25 (62.5%)
Phase 32 (25.0%)

Trials by Status

terminated113%
active_not_recruiting113%
recruiting675%

Recent Activity

7 active trials
Showing 5 of 8
recruitingphase_3

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

NCT07412613
terminatedphase_2

A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

NCT06851104
recruitingphase_2

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

NCT07263919
active_not_recruitingphase_2

Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

NCT06448910
recruitingphase_1

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

NCT06762080
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT07412613Phase 3

Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer

Recruiting
NCT06851104Phase 2

A Prospective Study of Cadonilimab in Hepatocellular Carcinoma After Radical Surgery With High Risk of Recurrence

Terminated
NCT07263919Phase 2

Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC)

Recruiting
NCT06448910Phase 2

Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC

Active Not Recruiting
NCT06762080Phase 1

Intrathecal Combination of Programmed Death-1 (PD-1)/Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Bispecific Antibody and Pemetrexed for Leptomeningeal Metastasis

Recruiting
NCT06617416Phase 3

A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC

Recruiting
NCT06401005Phase 2

SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)

Recruiting
NCT06467500Phase 2

A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy

Recruiting

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8